Gastrointestinal Conditions News

SAN DIEGO — Starting college can be tough for anyone, but students with inflammatory bowel disease have a greater risk for poor adjustment to college life, according to results of a prospective study presented at Digestive Disease Week.

WHO announced today that it has partnered with the Democratic Republic of the Congo, or DRC, Ministry of Health to provide more than 800,000 people with cholera immunizations. Gavi, the Vaccine Alliance, will fund the initiative, which will be implemented in North Kivu, in the eastern part of the DRC.

Researchers who planned a Fasciola treatment trial in 2017 with triclabendazole, or TCBZ, in the Bolivia Altiplano — a region previously known to have the highest prevalence and intensity of human fascioliasis— were not able to identify enough people with the condition.

SAN DIEGO — Adolescents and young adults demonstrated high levels of health literacy compared with their physicians as well as satisfaction with their medical records, according to data presented at Digestive Disease Week.

SAN DIEGO — Implementing a practice-wide therapeutic drug monitoring program may help improve several significant clinical outcomes in children with inflammatory bowel disease, according to study results presented at Digestive Disease Week.

SAN DIEGO — The Crohn’s Disease Exclusion Diet appeared to be an effective and well-tolerated, first-line therapy for children with mild-to-moderate Crohn’s disease, according to data presented at Digestive Disease Week.

A recent study published in mBio suggested that treatment with albendazole for hookworms and roundworms did not have a harmful effect on patients’ gut microbiome composition.

The FDA has given fast track designation to Finch Therapeutics’ Full-Spectrum Microbiota, or FSM, therapy for children with autism spectrum disorder, according to the company.

Nearly one-quarter of children with autism spectrum disorder have pica — an eating disorder involving the eating of nonfood items — according to research presented at the CDC’s Epidemic Intelligence Service Conference.

The FDA approved Mavyret to treat all six genotypes of hepatitis C in pediatric patients aged 12 years to 17 years, according to a press release from the organization.